Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.

Mixture-of-Recursions (MoR) is a new AI architecture that promises to cut LLM inference costs and memory use without ...